Collins Helen Louise insider trades
Collins Helen Louise has filed 27 Form 4s with the SEC that we hold, for Enliven Therapeutics, Inc. (ELVN) (CHIEF MEDICAL OFFICER), Kura Oncology, Inc. (KURA) (Director) and IO Biotech, Inc. (IOBT) (Director). Across all of them we count 0 purchases worth $0 and 27 sales worth $6.1M reported on Form 4. In the last 12 months: 0 purchases ($0) and 25 sales ($5.6M). The largest single trade was a sale of 40,000 shares of Enliven Therapeutics, Inc. worth $1.4M, dated 2026-03-25. Of 4 sales filed since we began reading the 10b5-1 checkbox, 4 (100%) were marked as made under a 10b5-1 trading plan. The first filing on our record is dated 2021-07-29 and the latest 2026-10-21.
Enliven Therapeutics, Inc. (ELVN)
| Trade date | Code | Shares | Value as filed | Filed | Source |
|---|---|---|---|---|---|
| 2024-04-11 | S, sale reported on Form 4 | 20,000 | $501.4K | 2024-04-15 | SEC |
| 2024-10-18 | S, sale reported on Form 4 | 816 | $24.5K | 2024-10-22 | SEC |
| 2026-02-17 | S, sale reported on Form 4 | 45,000 | $1.2M | 2026-02-19 | SEC |
| 2026-03-09 | S, sale reported on Form 4 | 29,871 | $896.7K | 2026-03-11 | SEC |
| 2026-03-10 | S, sale reported on Form 4 | 10,129 | $305.8K | 2026-03-11 | SEC |
| 2026-03-17 | S, sale reported on Form 4 | 5,000 | $138.8K | 2026-03-19 | SEC |
| 2026-03-25 | S, sale reported on Form 4 | 40,000 | $1.4M | 2026-03-27 | SEC |
| 2026-04-17 | S, sale reported on Form 4 | 2,441 | $117.3K | 2026-04-21 | SEC |
| 2026-04-17 | S, sale reported on Form 4 | 140 | $6.4K | 2026-04-21 | SEC |
| 2026-04-17 | S, sale reported on Form 4 | 2,419 | $114.6K | 2026-04-21 | SEC |
| 2026-05-18 | S, sale reported on Form 4 | 1,302 | $52.4K | 2026-05-20 | SEC |
| 2026-05-18 | S, sale reported on Form 4 | 3,475 | $137.4K | 2026-05-20 | SEC |
| 2026-05-18 | S, sale reported on Form 4 | 223 | $9.2K | 2026-05-20 | SEC |
| 2026-06-17 | S, sale reported on Form 4 | 1,268 | $54.3K | 2026-06-22 | SEC |
| 2026-06-17 | S, sale reported on Form 4 | 2,599 | $114.0K | 2026-06-22 | SEC |
| 2026-06-17 | S, sale reported on Form 4 | 1,133 | $50.7K | 2026-06-22 | SEC |
| 2026-07-17 | S, sale reported on Form 4 | 231 | $11.6K | 2026-07-21 | SEC |
| 2026-07-17 | S, sale reported on Form 4 | 459 | $23.7K | 2026-07-21 | SEC |
| 2026-07-17 | S, sale reported on Form 4 | 2,063 | $108.1K | 2026-07-21 | SEC |
| 2026-07-17 | S, sale reported on Form 4 | 2,184 | $116.7K | 2026-07-21 | SEC |
| 2026-07-17 | S, sale reported on Form 4 | 63 | $3.4K | 2026-07-21 | SEC |
| 2026-08-17 | S, sale reported on Form 4 | 3,900 | $227.6K | 2026-08-19 | SEC |
| 2026-08-17 | S, sale reported on Form 4 | 1,100 | $65.3K | 2026-08-19 | SEC |
| 2026-09-17 | S, sale reported on Form 4 | 2,916 | $145.9K | 2026-09-21 | SEC |
| 2026-09-17 | S, sale reported on Form 4 | 1,844 | $93.5K | 2026-09-21 | SEC |
| 2026-09-17 | S, sale reported on Form 4 | 240 | $12.4K | 2026-09-21 | SEC |
| 2026-10-19 | S, sale reported on Form 4 | 5,000 | $192.3K | 2026-10-21 | SEC |
Kura Oncology, Inc. (KURA)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
IO Biotech, Inc. (IOBT)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Counted from the Form 4 filings this reporting owner (SEC CIK 1701247) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
